News Focus
News Focus
icon url

User-840664

03/12/24 9:58 PM

#678179 RE: Nemesis18 #678178

I agree, and.... Poly ICLA is also NOT APPROVED and still in early stages, also not sponsored by NWBO
icon url

XMaster2023

03/12/24 11:54 PM

#678189 RE: Nemesis18 #678178

Sure thing NICE won’t pay. Approval is a few weeks away and you know it.
icon url

norisknorewards

03/13/24 12:24 AM

#678196 RE: Nemesis18 #678178

Go to bed
icon url

sentiment_stocks

03/13/24 11:56 AM

#678305 RE: Nemesis18 #678178

I don’t anticipate the cost of DCVax-L, after approval, to be £250k… more like £150k. And once Flaskworks is implemented, the price lessen by even more.

Additionally, I believe the company intends to sell the first four or so vaccines for use over a month or two, instead of all at once when the doses have been manufactured. The remaining doses would then be sold to the patient according to the dosage schedule. That is how I believe the company intends to sell the vaccine… although I could be wrong.

Such a distribution and pricing arrangement would help to make DCVax-L more affordable to the U.K. govt., IMO.
icon url

learningcurve2020

03/13/24 1:20 PM

#678326 RE: Nemesis18 #678178

I thought just maybe the MHRA might contribute something to a "Go fund me" raise for a GBM patient. But nothing that would be recognizable as revenues to drive share price.